Related Experiment Video

Updated: Jun 19, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Epigenetic changes in therapy-related MDS/AML

Maria Teresa Voso1, Francesco D'Alò, Mariangela Greco

  • 1Istituto di Ematologia, Università Cattolica Sacro Cuore, Largo A Gemelli 8, 00168Rome, Italy. mtvoso@rm.unicatt.it

Chemico-Biological Interactions
|October 31, 2009
PubMed

Insights

Chemo-radiotherapy can cause therapy-related Myelodysplastic Syndromes/Acute Myeloid Leukemias (t-MDS/AML) by altering DNA methylation. Promoter hypermethylation is frequent in t-MDS/AML, potentially driving secondary leukemia development.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Hematology

Background:

  • Therapy-related Myelodysplastic Syndromes/Acute Myeloid Leukemias (t-MDS/AML) are serious long-term effects of cancer treatments.
  • DNA methylation abnormalities, including global hypomethylation and promoter-specific hypermethylation, are implicated in secondary leukemogenesis.
  • Chemo-radiotherapy can induce DNA methylation changes in both treated and non-target tissues.

Purpose of the Study:

  • To investigate the role of DNA methylation alterations in the development of t-MDS/AML.
  • To identify specific gene promoter methylation patterns associated with t-MDS/AML.
  • To compare methylation profiles in t-MDS/AML with de novo MDS/AML.

Main Methods:

  • Analysis of DNA methylation profiles in patients with t-MDS/AML.
  • Assessment of promoter methylation for specific genes (e.g., p15, DAPK).
  • Comparison of concurrent promoter methylation frequencies between t-MDS/AML and de novo MDS/AML cohorts.

Main Results:

  • Gene promoter methylation is common in t-MDS/AML, correlating with shorter latency periods.
  • p15 methylation was linked to chromosome 7q abnormalities, suggesting a role in alkylating agent-induced leukemogenesis.
  • DAPK methylation was frequent in t-MDS/AML, particularly in patients with prior lymphoproliferative disease.
  • t-MDS/AML patients showed significantly higher frequencies of hypermethylation in multiple promoter regions compared to de novo MDS/AML.
  • Hypermethylation frequently affected genes involved in cell cycle control, apoptosis, and DNA repair pathways.

Conclusions:

  • Promoter hypermethylation of critical genes is a frequent epigenetic event in t-MDS/AML.
  • These epigenetic alterations may contribute significantly to the development of secondary leukemias after chemo-radiotherapy.
  • Further research is needed to elucidate the mechanisms by which chemo-radiotherapy disrupts epigenetic regulation during secondary carcinogenesis.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...